Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018
SUMMARY
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Malignant Mesothelioma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Ovarian Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor and T-Cell Lymphomas.
Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Malignant Mesothelioma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Ovarian Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor and T-Cell Lymphomas.
Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
- The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Overview
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
AstraZeneca Plc
Complix NV
Les Laboratoires Servier SAS
Takeda Pharmaceutical Co Ltd
Warp Drive Bio Inc
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles
AMG-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5991 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-63845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-64315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMI-77 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Products
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Product Development Milestones
Featured News & Press Releases
Dec 14, 2017: Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets
Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment
Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
Oct 20, 2016: New compound shows promise in treating multiple human cancers
Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Overview
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
AstraZeneca Plc
Complix NV
Les Laboratoires Servier SAS
Takeda Pharmaceutical Co Ltd
Warp Drive Bio Inc
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles
AMG-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5991 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-63845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-64315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMI-77 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Products
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Product Development Milestones
Featured News & Press Releases
Dec 14, 2017: Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets
Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment
Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
Oct 20, 2016: New compound shows promise in treating multiple human cancers
Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Complix NV, H1 2018
Pipeline by Les Laboratoires Servier SAS, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Warp Drive Bio Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Complix NV, H1 2018
Pipeline by Les Laboratoires Servier SAS, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Warp Drive Bio Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
AstraZeneca Plc
Complix NV
Les Laboratoires Servier SAS
Takeda Pharmaceutical Co Ltd
Warp Drive Bio Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
AstraZeneca Plc
Complix NV
Les Laboratoires Servier SAS
Takeda Pharmaceutical Co Ltd
Warp Drive Bio Inc
